VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LIVN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LIVNLivaNova PLC
$92.44$5.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. LIVN
  4. Financial Ratios

LivaNova PLC (LIVN) Financial Ratios

Latest Ratios: P/E Ratio 27.1x · EV/EBITDA 19.9x · ROE -19.2%. (1995–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

LIVN Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$5.1B$3.4B$2.5B$2.8B$3.0B$4.4B$3.2B$3.6B$4.4B$3.9B$2.2B
Enterprise Value$4.9B$3.2B$2.8B$3.2B$3.3B$4.5B$3.7B$4.0B$4.6B$3.9B$2.3B
P/E Ratio →27.06—39.92161.69———————
P/S Ratio3.372.422.022.432.914.283.443.364.013.831.81
P/B Ratio4.202.791.912.202.463.422.902.642.952.141.29
P/FCF39.3819.3618.5970.2468.4757.44——53.7767.7641.49
P/OCF19.9713.1913.8137.4442.5143.17——36.8142.4524.38

P/E links to full P/E history page with 30-year chart

LIVN EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—2.302.212.763.274.353.933.674.123.881.88
EV / EBITDA19.8513.2215.40——67.04———23.6839.51
EV / EBIT24.65—18.33————82.09—30.4763.70
EV / FCF—18.4220.4279.6076.9058.46——55.2468.6843.06

LIVN Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin67.7%67.7%69.5%66.9%69.2%68.2%63.7%66.8%66.4%64.4%58.0%
Operating Margin14.4%14.4%10.3%-5.9%-7.5%-0.1%-29.3%-15.8%-22.4%9.5%-2.3%
Net Profit Margin-17.5%-17.5%5.0%1.5%-8.4%-13.1%-37.3%-14.5%-17.1%-2.5%-5.2%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-19.2%-19.2%4.9%1.4%-6.9%-11.3%-28.0%-10.9%-11.4%-1.4%-3.6%
ROA-9.5%-9.5%2.6%0.7%-3.8%-5.9%-14.5%-6.4%-7.5%-1.0%-2.6%
ROIC11.5%11.5%6.0%-3.2%-3.9%-0.0%-12.5%-7.7%-10.7%3.9%-1.1%
ROCE10.2%10.2%6.1%-3.3%-4.4%-0.0%-13.7%-8.7%-12.0%4.6%-1.3%

LIVN Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.390.390.510.500.480.220.640.290.110.080.07
Debt / EBITDA1.961.963.76——4.27———0.882.13
Net Debt / Equity—-0.140.190.290.300.060.410.240.080.030.05
Net Debt / EBITDA-0.67-0.671.38——1.17———0.321.44
Debt / FCF—-0.941.829.368.441.02——1.470.921.57
Interest Coverage-3.48-3.482.40-0.38-0.56-1.48-1.493.21-24.1916.543.37

Net cash position: cash ($636M) exceeds total debt ($473M)

LIVN Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.361.362.872.952.980.972.291.071.072.141.96
Quick Ratio1.161.162.502.512.540.821.920.750.761.791.38
Cash Ratio0.790.791.090.800.720.300.820.120.100.230.13
Asset Turnover—0.530.500.470.450.470.390.450.430.400.52
Inventory Turnover2.722.722.592.592.433.112.942.202.432.502.78
Days Sales Outstanding—56.8065.1468.0576.7478.6172.3486.9884.44103.2064.12

LIVN Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield3.7%—2.5%0.6%———————
FCF Yield2.5%5.2%5.4%1.4%1.5%1.7%——1.9%1.5%2.4%
Buyback Yield0.1%0.1%0.3%0.3%0.3%0.3%0.2%0.2%1.4%0.1%2.5%
Total Shareholder Yield0.1%0.1%0.3%0.3%0.3%0.3%0.2%0.2%1.4%0.1%2.5%
Shares Outstanding—$55M$55M$54M$54M$51M$49M$48M$48M$49M$49M

Key Metrics

Growth RegimeStable
ProfitabilityStrained
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Non-operating charges eroding earnings

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Negative Trailing Earnings Distort Multiples

Based on reported figures, LIVN trades at a trailing P/E of -20.22 but a forward P/E of 20.66, and the swing suggests the market is pricing recovery rather than current earnings power.

The gap between a negative trailing P/E and a forward P/E near 21x indicates that trailing multiples are largely uninformative given the large non-operating losses in recent quarters. The forward EV/EBITDA of 11.32 versus a trailing 19.81 implies that consensus expects EBITDA to expand meaningfully, which investors should test against the operating margin compression seen from 15.4% to 7.2%. Relative to peers, the P/B of 4.09 appears elevated given a negative ROE of -19.2%, suggesting the price relies on the durability of the installed VNS and Essenz base.

Operating Margin Erosion Versus Net Losses

Reported operating margin fell from 15.4% in 2025Q2 to 7.2% in 2026Q3, while the trailing net margin of -17.5% indicates non-operating items are absorbing most of the operating profit.

Gross margins have held in a tight 66% to 71% band, so the compression is occurring below gross profit, pointing to rising operating expense intensity rather than pricing or input cost pressure. The divergence between a positive operating margin and a negative trailing net margin suggests interest, impairments, or litigation charges are doing the damage, which warrants reconciliation against GAAP filings. Operating margin, not net margin, is the better gauge of underlying earnings power, though it should be adjusted for recurring restructuring costs before being treated as sustainable.

Deleveraging Progress Against Thin Coverage

Debt-to-equity fell from 0.55 in 2024Q2 to 0.25 in 2026Q3, and interest coverage of 6.85x in the latest quarter suggests debt service is comfortable on current figures.

The reduction in D/E and D/EBITDA from 13.95 to 6.35 indicates the company is materially less levered than two years ago, though interest coverage has been volatile, swinging from 2.40x to 13.69x on reported quarterly figures. Coverage ratios are sensitive to quarterly EBITDA timing, so the trend warrants monitoring rather than being taken at face value. The deleveraging appears to have been funded partly by cash balances rather than sustained profitability, which suggests the improvement may be less durable than the headline ratio implies.

Current Ratio Normalizing From Elevated Levels

According to reported figures, the current ratio declined from 3.45 in 2024Q2 to 1.46 in 2026Q3, and the quick ratio of 1.22 still indicates a reasonable cushion without reliance on inventory.

The decline in current ratio reflects a shift in working capital composition rather than a deterioration in ability to meet near-term obligations, since quick ratio remains above 1.0. The cash conversion cycle has moved from 131 days to 116 days, driven by a lengthening DPO and a shorter DSO, which suggests improved receivables management. Under severe stress, the position would likely remain adequate given the quick ratio, though the dependence on cash balances for liquidity warrants investor attention.

Asset Turnover Masks Reinvestment Pressure

The asset turnover ratio of 0.15 and rising capital expenditure at roughly 7.8% of revenue suggest the company's capital base is growing faster than its revenue generation.

A low asset turnover of 0.15 is typical of a medical device business with significant intangible and fixed asset intensity, so the metric should be read against peers rather than in isolation. The step-up in capex from 3.2% to 7.8% of revenue may reflect platform investment that could support future margins, but it also raises the question of whether returns on invested capital, currently around 1.8%, will recover. The most commonly misapplied metric here is ROE, which is distorted by the accumulated deficit and recent equity rebuilding, and investors should instead anchor on ROIC and operating margin trends.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus & Technical Research Suite
Open LIVN Terminal

LIVN Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

LIVN — Frequently Asked Questions

Quick answers to the most common questions about buying LIVN stock.

What is LivaNova PLC's P/E ratio?

LivaNova PLC's current P/E ratio is 27.1x. The historical average is 100.8x.

What is LivaNova PLC's EV/EBITDA?

LivaNova PLC's current EV/EBITDA is 19.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 31.8x.

What is LivaNova PLC's ROE?

LivaNova PLC's return on equity (ROE) is -19.2%. The historical average is -18.7%.

Is LIVN stock overvalued?

Based on historical data, LivaNova PLC is trading at a P/E of 27.1x. Compare with industry peers and growth rates for a complete picture.

What are LivaNova PLC's profit margins?

LivaNova PLC has 67.7% gross margin and 14.4% operating margin. Operating margin between 10-20% is typical for established companies.

How much debt does LivaNova PLC have?

LivaNova PLC's Debt/EBITDA ratio is 2.0x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.